PDF(Pubmed)
Abstract：
The aim of our study was to evaluate the efficacy of cariprazine augmentation of clozapine in treatment-resistant schizophrenia in a retrospective chart review. Among 916 medical records of schizophrenia patients, we identified 12 individuals treated with a combination of those drugs for a duration of 3-60 weeks [median 32 (10-40)]. Clinical Global Impression-Improvement (CGI-I) scores were used to measure the treatment response between the introduction of cariprazine augmentation of clozapine and the last point of observation. The majority of the patients presented treatment response (9/12 patients, 75%) after 4-16 weeks of therapy [median 6 (4-12)]. Treatment was associated with the decrease in positive, negative, affective, and anxiety symptom severity, as well as improvement of patient global functioning. One patient discontinued the treatment due to side effects (akathisia), and two patients halted the therapy due to the exacerbation of psychotic symptoms. Our study presents a thorough clinical description of the largest number of treatment-resistant schizophrenia patients medicated using cariprazine augmentation of clozapine in a \"real-world\" setting. Our results suggest that the use of this combination may lead to the improvement in a broad range of symptoms of patients with this condition.
摘要：
我们研究的目的是在回顾性图表综述中评估卡利拉嗪增强氯氮平在难治性精神分裂症中的疗效。在916份精神分裂症患者的医疗记录中，我们确定了12例接受这些药物联合治疗3~60周的患者[中位数32(10~40)].临床总体印象改善（CGI-I）评分用于测量引入卡利拉嗪增强氯氮平与最后观察点之间的治疗反应。大多数患者出现治疗反应(9/12患者，75％）治疗4-16周后[中位数6（4-12）]。治疗与阳性降低有关，负,情感,和焦虑症状的严重程度，以及改善患者的整体功能。一名患者因副作用（静坐不能）停止治疗，两名患者因精神病症状加重而停止治疗。我们的研究提供了在“现实世界”环境中使用卡利拉嗪增强氯氮平的最大数量的难治性精神分裂症患者的全面临床描述。我们的结果表明，使用这种组合可能会改善患有这种疾病的患者的广泛症状。
